DK0819010T3 - Proteinformuleringer omfattende koagulationsfaktor VIII eller IX i en vandig sucroseopløsning - Google Patents

Proteinformuleringer omfattende koagulationsfaktor VIII eller IX i en vandig sucroseopløsning

Info

Publication number
DK0819010T3
DK0819010T3 DK96909444T DK96909444T DK0819010T3 DK 0819010 T3 DK0819010 T3 DK 0819010T3 DK 96909444 T DK96909444 T DK 96909444T DK 96909444 T DK96909444 T DK 96909444T DK 0819010 T3 DK0819010 T3 DK 0819010T3
Authority
DK
Denmark
Prior art keywords
solution
pct
factor viii
coagulation factor
concentration
Prior art date
Application number
DK96909444T
Other languages
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of DK0819010T3 publication Critical patent/DK0819010T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK96909444T 1995-03-31 1996-03-29 Proteinformuleringer omfattende koagulationsfaktor VIII eller IX i en vandig sucroseopløsning DK0819010T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501189A SE9501189D0 (sv) 1995-03-31 1995-03-31 Protein formulation
PCT/SE1996/000419 WO1996030041A1 (en) 1995-03-31 1996-03-29 Protein formulation comprising coagulation factor viii or factor ix in an aqueous solution

Publications (1)

Publication Number Publication Date
DK0819010T3 true DK0819010T3 (da) 2004-02-09

Family

ID=20397788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909444T DK0819010T3 (da) 1995-03-31 1996-03-29 Proteinformuleringer omfattende koagulationsfaktor VIII eller IX i en vandig sucroseopløsning

Country Status (14)

Country Link
US (1) US5919908A (da)
EP (1) EP0819010B1 (da)
JP (1) JP3953102B2 (da)
AT (1) ATE251467T1 (da)
AU (1) AU709642B2 (da)
BR (1) BR9607922A (da)
CA (1) CA2216098C (da)
DE (1) DE69630291T2 (da)
DK (1) DK0819010T3 (da)
ES (1) ES2208736T3 (da)
NZ (1) NZ305028A (da)
PT (1) PT819010E (da)
SE (1) SE9501189D0 (da)
WO (1) WO1996030041A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
NZ516664A (en) * 1999-07-15 2003-06-30 Inst Genetics Llc Formulations and compositions for interleukin-11
KR100929078B1 (ko) * 2001-11-29 2009-11-30 파나소닉 주식회사 코딩 왜곡 제거 방법
JP2005535644A (ja) * 2002-06-26 2005-11-24 ファルマシア コーポレイション 安定な非経口パレコキシブ液体製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DK1599222T3 (da) * 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
BRPI0408925A (pt) * 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
AU2008340304B2 (en) * 2007-12-21 2016-03-03 Aptevo Biotherapeutics Llc Stabilized factor IX formulations containing trehalose
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
GB0915481D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AU2011219612A1 (en) * 2010-02-24 2012-09-06 Arecor Limited Stable compositions of Factor IX
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
JP2019043961A (ja) * 2010-04-20 2019-03-22 オクタファルマ・アーゲー 医薬タンパク質の新規な安定化剤
CN103003422B (zh) * 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
FR2687317B1 (fr) * 1992-02-13 1995-06-23 Aetsrn Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique.
DE4205192C2 (de) * 1992-02-20 1995-10-12 Euka Bauelemente Verkaufsgesel Bahnsteig
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
CN1064552C (zh) * 1993-02-09 2001-04-18 奥克塔法马有限公司 失活无脂质被膜病毒的方法
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency

Also Published As

Publication number Publication date
US5919908A (en) 1999-07-06
DE69630291D1 (de) 2003-11-13
EP0819010A1 (en) 1998-01-21
ES2208736T3 (es) 2004-06-16
ATE251467T1 (de) 2003-10-15
PT819010E (pt) 2004-01-30
SE9501189D0 (sv) 1995-03-31
WO1996030041A1 (en) 1996-10-03
AU709642B2 (en) 1999-09-02
CA2216098C (en) 2011-08-23
CA2216098A1 (en) 1996-10-03
BR9607922A (pt) 1998-06-09
AU5293496A (en) 1996-10-16
DE69630291T2 (de) 2004-05-06
EP0819010B1 (en) 2003-10-08
JPH11502833A (ja) 1999-03-09
JP3953102B2 (ja) 2007-08-08
NZ305028A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
SE9501189D0 (sv) Protein formulation
EE03118B1 (et) Proteiinravim ja selle valmistamismeetod
Vodovotz et al. Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with IFN-gamma and bacterial lipopolysaccharide.
Boright et al. A dissociation between the adrenal and extra-adrenal actions of corticotrophin by periodate oxidation
ES2150940T3 (es) Formulacion proteinica que comprende hormona del crecimiento.
US6087338A (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
AU5909498A (en) Formulations for amylin agonist peptides
JPH01311027A (ja) ヒトのアルブミン溶液の安定化方法と、それによって得られた溶液
TW420614B (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation
Boat et al. Toxic effects of oxygen on cultured human neonatal respiratory epithelium
Shackney et al. Stimulation of glucose metabolism in brown adipose tissue by addition of insulin in vitro
Skala et al. Portein kinases in brown adipose tissue of developing rats. State of activation of protein kinase during development and cold exposure and its relationship to adenosine 3': 5'-monophosphate, lipolysis, and heat production.
HUT67321A (en) Transdermal preparations containing lanolin derivatives as penetration- promoting agent
CA2067371A1 (en) Stable hemoglobin based composition and method to store same
HUP9603489A2 (hu) Gyógyszerkészítmény és eljárás előállítására
Lea et al. Divergent effects of cyanate on amino acid and phosphate uptake by liver and hepatoma
Lee et al. Effect of Aspergillus fumigatus endotoxin on the respiration and phosphorylation of kidney tissue
Levy et al. Effects of inflammation on proteins and enzymes in rat plasma
SE9402119D0 (sv) Solution
Bertolami et al. The effect of skin grafting upon prolyl hydroxylase and hyaluronidase activities in mammalian wound repair
Henderson et al. Deuterium isotope effects on histone synthesis in avian erythroblasts
Tasir et al. The time-dependent effect of exogenous epidermal growth factor administration on oxidant events in submandibular glands of New Zeland-type male rabbits
MD542G2 (ro) Metodă de termografie activă a glandelor mamare